Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Health Care sector as a whole closed the day down 0.3% versus the S&P 500, which was down 0.3%. Laggards within the Health Care sector included XTL Biopharmaceuticals ( XTLB), down 4.0%, ProPhase Labs ( PRPH), down 1.9%, SunLink Health Systems ( SSY), down 2.8%, CAS Medical Systems ( CASM), down 2.2% and Tianyin Pharmaceutical ( TPI), down 1.8%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the sector lower today:

Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies that pushed the Health Care sector lower today. Fresenius Medical Care AG & Co. KGaA was down $1.05 (2.8%) to $36.29 on average volume. Throughout the day, 179,426 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 127,400 shares. The stock ranged in price between $36.24-$36.53 after having opened the day at $36.39 as compared to the previous trading day's close of $37.34.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides renal dialysis products and services. Fresenius Medical Care AG & Co. KGaA has a market cap of $22.4 billion and is part of the health services industry. Shares are up 0.5% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate Fresenius Medical Care AG & Co. KGaA a buy, 1 analyst rates it a sell, and 4 rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from TheStreet Ratings analysis on FMS go as follows:

  • Despite its growing revenue, the company underperformed as compared with the industry average of 20.5%. Since the same quarter one year prior, revenues rose by 12.2%. This growth in revenue does not appear to have trickled down to the company's bottom line, displaying stagnant earnings per share.
  • The debt-to-equity ratio is somewhat low, currently at 0.96, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.87 is somewhat weak and could be cause for future problems.
  • Net operating cash flow has increased to $712.21 million or 17.62% when compared to the same quarter last year. Despite an increase in cash flow, FRESENIUS MEDICAL CARE AG&CO's cash flow growth rate is still lower than the industry average growth rate of 53.34%.
  • 35.63% is the gross profit margin for FRESENIUS MEDICAL CARE AG&CO which we consider to be strong. Regardless of FMS's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, FMS's net profit margin of 6.58% compares favorably to the industry average.
  • In its most recent trading session, FMS has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.

You can view the full analysis from the report here: Fresenius Medical Care AG & Co. KGaA Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, CAS Medical Systems ( CASM) was down $0.03 (2.2%) to $1.35 on heavy volume. Throughout the day, 81,141 shares of CAS Medical Systems exchanged hands as compared to its average daily volume of 23,700 shares. The stock ranged in price between $1.34-$1.40 after having opened the day at $1.36 as compared to the previous trading day's close of $1.38.

CAS Medical Systems, Inc., a medical technology company, develops, manufactures, and markets medical devices for non-invasive patient monitoring in the United States and internationally. CAS Medical Systems has a market cap of $30.6 million and is part of the health services industry. Shares are down 4.8% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates CAS Medical Systems a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates CAS Medical Systems as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk.

Highlights from TheStreet Ratings analysis on CASM go as follows:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, CAS MEDICAL SYSTEMS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Currently the debt-to-equity ratio of 1.60 is quite high overall and when compared to the industry average, suggesting that the current management of debt levels should be re-evaluated. Regardless of the company's weak debt-to-equity ratio, CASM has managed to keep a strong quick ratio of 2.00, which demonstrates the ability to cover short-term cash needs.
  • CASM's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 27.91%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • CAS MEDICAL SYSTEMS INC has improved earnings per share by 47.4% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CAS MEDICAL SYSTEMS INC reported poor results of -$0.74 versus -$0.64 in the prior year. This year, the market expects an improvement in earnings (-$0.46 versus -$0.74).
  • The gross profit margin for CAS MEDICAL SYSTEMS INC is rather high; currently it is at 51.76%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -30.50% is in-line with the industry average.

You can view the full analysis from the report here: CAS Medical Systems Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

XTL Biopharmaceuticals ( XTLB) was another company that pushed the Health Care sector lower today. XTL Biopharmaceuticals was down $0.08 (4.0%) to $2.02 on light volume. Throughout the day, 5,768 shares of XTL Biopharmaceuticals exchanged hands as compared to its average daily volume of 8,500 shares. The stock ranged in price between $1.97-$2.17 after having opened the day at $1.99 as compared to the previous trading day's close of $2.10.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. XTL Biopharmaceuticals has a market cap of $23.8 million and is part of the health services industry. Shares are up 6.2% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate XTL Biopharmaceuticals a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates XTL Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on XTLB go as follows:

  • XTL BIOPHARMACEUTICALS has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, XTL BIOPHARMACEUTICALS reported poor results of -$0.22 versus -$0.13 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 192.9% when compared to the same quarter one year ago, falling from $0.55 million to -$0.51 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, XTL BIOPHARMACEUTICALS's return on equity significantly trails that of both the industry average and the S&P 500.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 44.45%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 200.00% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The gross profit margin for XTL BIOPHARMACEUTICALS is rather high; currently it is at 61.67%. Despite the high profit margin, it has decreased significantly from the same period last year. Despite the mixed results of the gross profit margin, XTLB's net profit margin of -177.70% significantly underperformed when compared to the industry average.

You can view the full analysis from the report here: XTL Biopharmaceuticals Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.